Myriad Genetics Inc
MYGN- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000899923
No open-market purchases or sales by Myriad Genetics Inc insiders were filed in the last 90 days; 196 institutions reported holding it in 13F filings for Q2 2026, worth $507.8M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Myriad Genetics Inc changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 194 | 186 | −8 |
| Shares | 89.9M | 93.8M | +3.94M (+4.4%) |
| Value | $1.72B | $2.00B | +$280.4M (+16.3%) |
New holders (21)
Institutions that held Myriad Genetics Inc at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Point72 Asset Management, L.P. | 778,196 | $16.6M | 0.05% |
| First Trust Advisors LP | 116,743 | $2.49M | 0.00% |
| AMH Equity Ltd | 110,000 | $2.35M | 2.59% |
| ExodusPoint Capital Management, LP | 79,066 | $1.69M | 0.02% |
| Marshall Wace, LLP | 33,557 | $715.4K | 0.00% |
| Toroso Investments, LLC | 28,432 | $606.2K | 0.01% |
| UniSuper Management Pty Ltd | 21,917 | $467.3K | 0.00% |
| Fox Run Management, L.L.C. | 17,120 | $365.0K | 0.08% |
| E Fund Management Co., Ltd. | 11,776 | $251.1K | 0.02% |
| Aquatic Capital Management LLC | 4,900 | $104.5K | 0.00% |
| Pacer Advisors, Inc. | 1,160 | $24.7K | 0.00% |
| Crewe Advisors LLC | 1,000 | $21.3K | 0.00% |
| CIBC Private Wealth Group, LLC | 400 | $8.58K | 0.00% |
| Oliver Lagore Vanvalin Investment Group | 220 | $4.69K | 0.00% |
| Smartleaf Asset Management LLC | 174 | $3.72K | 0.00% |
| Smithfield Trust Co | 84 | $2.00K | 0.00% |
| Koesten, Hirschmann & Crabtree, INC. | 55 | $1.17K | 0.00% |
| Quest Partners LLC | 49 | $1.04K | 0.00% |
| Umb Bank N A | 36 | $768 | 0.00% |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 16 | $341 | 0.00% |
| Rothschild Investment LLC | 10 | $213 | 0.00% |
Sold out (29)
Institutions that held Myriad Genetics Inc at the end of Q4 2023 and filed for Q1 2024 without it.